key: cord-1049004-qo8ap7zy
authors: Sing, Chor‐Wing; Tang, Casey Tze Lam; Chui, Celine Sze Ling; Fan, Min; Lai, Francisco Tsz Tsun; Li, Xue; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Chan, Esther Wai Yin; Hung, Ivan Fan Ngai; Leung, Anskar Yu‐Hung; Cheung, Ching‐Lung; Wong, Ian Chi Kei
title: COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study
date: 2022-02-09
journal: Am J Hematol
DOI: 10.1002/ajh.26478
sha: b21f9ec476fa1acb73b9a3305fec1ea91e6580d0
doc_id: 1049004
cord_uid: qo8ap7zy

Several studies reported hematological abnormalities after vaccination against the coronavirus disease 2019 (COVID‐19). We evaluated the association between COVID‐19 vaccines (CoronaVac and BNT162b2) and hematological abnormalities. We conducted nested case–control and self‐controlled case series analyses using the data from the Hong Kong Hospital Authority and the Department of Health, HKSAR. Outcomes of interest were thrombocytopenia, leukopenia, and neutropenia. Adjusted odds ratios (aORs), incidence rate ratios (IRRs), and 95% confidence intervals (CIs) were estimated using conditional logistic regression. In total, 1 643 419 people received COVID‐19 vaccination (738 609 CoronaVac; 904 810 BNT162b2). We identified 457 and 422 cases after CoronaVac and BNT162b2 vaccination, respectively. For CoronaVac, the incidence of thrombocytopenia, leukopenia, and neutropenia was 2.51, 1.08, and 0.15 per 10 000 doses. For BNT162b2, the corresponding incidence was 1.39, 1.17, and 0.26 per 10 000 doses. The incidence per 10 000 COVID‐19 cases were 1254, 2341, and 884, respectively. We only observed an increased risk of leukopenia following the second dose of BNT162b2 (aOR 1.58, 95% CI 1.24–2.02; day 0–14, IRR 2.21; 95% CI 1.59–3.08). There was no increased risk of any hematological abnormalities after CoronaVac vaccination. We observed an increased risk of leukopenia shortly after the second dose of BNT162b2. However, the incidence was much lower than the incidence following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections. There was no association between CoronaVac and hematological abnormalities. The benefits of vaccination against COVID‐19 still outweigh the risk of hematological abnormalities.

any hematological abnormalities after CoronaVac vaccination. We observed an increased risk of leukopenia shortly after the second dose of BNT162b2. However, the incidence was much lower than the incidence following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. There was no association between CoronaVac and hematological abnormalities. The benefits of vaccination against COVID-19 still outweigh the risk of hematological abnormalities.

The coronavirus disease 2019 (COVID-19) pandemic has infected over 209 million people and caused more than 4.3 million deaths worldwide, as of August 2021. 1 Vaccination is considered the most effective mean of controlling the pandemic. Traditional inactivated vaccines 2, 3 and new viral vector-mRNA vaccines 4, 5 have been developed with proven efficacy against COVID-19 infections, hospitalization, and mortality. [6] [7] [8] Many countries have authorized the emergency use of the vaccines and started a national program of COVID-19 vaccination.

However, the safety of the COVID-19 vaccines has been a major concern to the public, resulting in vaccine hesitancy, especially those developed by the new mRNA technology. Several case series reported hematological abnormalities, including thrombocytopenia and immune thrombocytopenic purpura (ITP) after vector-based (e.g., ChAdOx1 nCoV-19) 9,10 or mRNA-based (e.g., BNT162b2) vaccination. 11, 12 The phase 1 and 2 clinical trials of ChAdOx1 nCoV-19 vaccine from AstraZeneca observed transient neutropenia in 46% of the recipients. 4 These findings indicated that the vaccines may trigger the immune response affecting the blood system.

Given that hematological abnormalities may result in life-threatening complications, estimating the risk of such serious adverse reactions is important. Currently, there is no real-world study concerning the hematological effects in inactivated vaccines, for example, CoronaVac.

Recent population-based studies [13] [14] [15] only investigated the risk of thrombocytopenia after COVID-19 vaccines. However, whether the vaccines are associated with other hematological abnormalities such as decreased white blood cells (WBC) counts remains unknown. We conducted a population-based study in Hong Kong to evaluate the association between hematological abnormalities (including thrombocytopenia, leukopenia, and neutropenia) and COVID-19 vaccines (CoronaVac and BNT162b2), using nested case-control and self-controlled case series (SCCS) analyses.

We conducted nested case-control and SCCS analyses to evaluate the association between COVID-19 vaccines and hematological abnormalities using patients in the Hong Kong Hospital Authority (HA). We also estimated the incidence of hematological abnormalities in people receiving COVID-19 vaccination and people tested positive in the SARS-CoV-2 test (COVID-19 cases), respectively. The mass COVID-19 vaccination program in Hong Kong has broadly included people from different sectors, including healthy individuals (the rollout schedule is described in Table S1 ). Thus, people receiving vaccination may be healthier than those without receiving vaccination. Such concern has been acknowledged in the previous studies. 13, 14 We, therefore, conducted SCCS analysis, a within-individual comparison, to further minimize such selection bias and control unmeasured confounding, in addition to the nested case-control analysis. 16 SCCS can be served as an internal validation for the results in the nested casecontrol analysis.

This study is part of the regulatory pharmacovigilance study initiated by the Department of Health (DH) of the Government of Hong Kong. Vaccination data were provided by the DH, which included all people receiving the COVID-19 vaccine in Hong Kong.

The Hong Kong government manages the allocation of vaccines to public and private sectors and tracks all individual vaccination records. Thus, data quality and representatives can be guaranteed.

The data have been used to study the risk of Bell's palsy associated with COVID-19 vaccines. 17 Vaccination records were linked to the clinical data from the electronic healthcare database that is managed by the HA, a statutory body that provides subsidized public healthcare services and serves over 80% of the Hong Kong population. 18 The database has been used to conduct the safety study of COVID-19 vaccines 17 and pharmacoepidemiological studies. [19] [20] [21] In this study, we acquired anonymized patient-level data between January 1, 2018 and July 31, 2021.

People aged ≥16 and who had ever used the HA service (inpatients, outpatients, or emergency) between January 1, 2018 and July 31, 2021 were included. We excluded those who had any medical conditions affecting the blood counts prior to the hematological abnormality. These conditions included (i) history of the same hematological abnormality; (ii) history of cancer; (iii) recent chemotherapy, radiotherapy, or use of drugs for malignant disease and immunosuppression within 90 days prior; and (iv) diseases affecting the blood cells (myelodysplastic syndromes, iron-vitamin B12 deficiency anemia, aplastic anemia, hypersplenism, chronic renal failure, viral infection, alcohol abuse-alcoholic liver diseases). We further excluded people with heparin use within 14 days prior to thrombocytopenia. 22 All diagnoses were defined by the International Classification of Diseases, Ninth Revision codes, whereas prescriptions were defined by British national formulary (BNF) or local drug codes (Table S2 ).

The COVID-19 Vaccination Program in Hong Kong provides free administration of CoronaVac and BNT162b2 since February 23, 2021 and March 6, 2021, respectively. 23 The recommended schedule after the first dose is 28 days for CoronaVac and 21 days for BNT162b2.

Recipients can schedule their second dose vaccination as long as it is not shorter than the recommended schedule. By July 2021, almost 60% of the Hong Kong population have received at least one dose of the vaccine. 23 

The outcomes of interest were thrombocytopenia, leukopenia, and neutropenia. To identify the events, we reviewed the laboratory records of platelet counts (<150 Â 10 9 /L for thrombocytopenia 24 ), total WBC counts (<4 Â 10 9 /L for leukopenia 25 ) , and neutrophil counts (<1.5 Â 10 9 /L for neutropenia 26 ) in people admitted to hospitals between February 23, 2021 and July 31, 2021. Given that hematological abnormalities could be asymptomatic, we reviewed the laboratory records 7 days before-after admission to identify the onset time of the event. The index date was the date of the first laboratory record fulfilling the outcome definition.

Incidence was defined as new onset of hematological abnormality since 2018. Apart from the incidence per vaccine doses administered, we also estimated the incidence per COVID-19 cases from January 23, 2020 (the first COVID-19 case in Hong Kong) to July 31, 2021. Cases were defined as the onset of the event within 28 days following vaccination or positive result of the SARS-CoV-2 test. We used 28 days as the time period to define cases, which is in line with the published literatures. 13, 14 Follow-up was censored on 28 days, date of death, end of the study period, whichever occurred earlier. For the first dose, follow-up was also censored on the date of the second dose vaccination. Severe thrombocytopenia and neutropenia may result in life-threatening complications such as internal bleeding and serious infections. Therefore, we further estimated the incidence for mild, moderate, and severe cases, according to the corresponding blood counts (Platelet counts <100-150, 50-100, <50 Â 10 9 /L, for thrombocytopenia 27 ; Neutrophil counts <1 to <1.5, 0.5-1, <0.5 Â 10 9 /L, for neutropenia 28 ).

People who had the outcome of interest were considered cases. Controls were those who were admitted to hospitals during the study period and had not yet experienced the outcome of interest. The index date for control was defined as the admission date. Exclusion criteria for controls were the same as the study cohort aforementioned. To minimize selection bias from healthier vaccine recipients, we further excluded people who were ever admitted to hospitals in the past 3 years. We matched cases and controls by age, sex, index date (±7 days), and the Charlson's comorbidity index (0, 1-2, 3-4, ≥5) at a ratio of 1:10, using random sampling with replacement. Cases with less than 10 matched controls were excluded.

Exposure of interest was the receipt of either CoronaVac or BNT162b2 within 28 days 14, 15 prior to the index date. Those who received the vaccine ≥28 days earlier than the index date were excluded. We evaluated the vaccine effect by dose. Cases that occurred within 28 days of the first dose and before the second dose were included for the analysis of first dose effect, whereas cases that occurred within 28 days of the second dose were included for the analysis of second dose effect.

In the study cohort, people who had the outcome of interest were included in the SCCS analysis. Observation period of an individual started from February 23, 2021 to July 31, 2021. For vaccinated people, the date of vaccination was considered day 0. A risk period was defined as the period from days 0-27 following the vaccination, which was stratified into days 0-13 and days 14-27. Control period was any other nonrisk periods within the observation period. Figure S1 illustrates the schema of SCCS design.

To ensure unbiased estimates, three assumptions should be met 16 : (1) events must be independently recurrent; (2) occurrence of an event should not affect subsequent exposure; and (3) events should not censor observation period. Thus, only first event was included because recurrent events could be dependent (violation of assumption 1). In addition, people with previous hematological abnormalities were unlikely to receive the vaccine (violation of assumption 2). Similarly, events that occurred after the first dose may decrease the probability of second dose vaccination. Thus, we applied the modified SCCS extension "eventdepenexp" in the R-package "SCCS,"

which is designed to fit the model with event-dependent exposures. 29 Cases without vaccination were included in the extension model for adjustment. Furthermore, we excluded people who died during the study (violation of assumption 3).

The numerator was the total number of cases after the first or second dose. The denominator was the number of doses administered or COVID-19 cases. Incidence rate (IR) and 95% confidence intervals (CIs) were estimated using Poisson regression.

Conditional logistic regression stratified by match pairs was used.

Standardized mean difference (SMD) of the baseline variables between matched cases and controls were calculated, and those with SMD <0.2 were adjusted in the model. The model was further adjusted for confounding variables, 30 Figure S2 . For sensitivity analysis using a longer time period, given a maximum follow-up period of 130 days for the second dose vaccination, almost 90% of hematological abnormality cases were captured within 84 days ( Figure S3 ). Given the small number of cases beyond 28 days, we split the risk period beyond 28 days into two 4-week periods, that is, day 28-55 and day 56-83 in the SCCS analysis.

T A B L E 2 People characteristics in self-controlled case series analysis (Table 4) . Similar findings were shown in the subgroup (Tables S4-S7) and additional analyses excluding COVD-19 cases (Tables S8 and S9 ).

In the sensitivity analysis examining the association beyond 28 days, no increased risk was observed in the nested case-control and SCCS analysis for both vaccines (Tables S10 and S11). Abbreviations: IR, incidence rate; IRR, incidence rate ratio; SCCS, self-controlled case series. a IRR was estimated using modified SCCS extension "eventdepenexp" model.

observed an increased risk of leukopenia following the second dose of BNT162b2 in the nested case-control analysis (aOR 1.58; 95% CI 1.24-2.02, Table 3 ). In the SCCS analysis, we further found that the increased risk was only significant within the first 2 weeks following the second dose (IRR 2.21; 95% CI 1.59-3.08, Table 4 ). The association remained significant after excluding COVID-19 cases (Tables S8   and S9 ). In subgroup analysis, we only observed similar results in people aged <60 years but not in people aged ≥60 years (Tables S4-S7) .

For the association beyond 28 days of vaccination, the findings in the nested case-control analysis were similar to the main analysis (Table S10 ). In the SCCS analysis, there was an increased risk on day 28-55 post second dose CoronaVac (IRR 2.15, 95% CI 1.25-3.71, Table S11 ).

We included 349 neutropenia cases in the nested case-control and 941 cases (686 unvaccinated, 95 CoronaVac, 160 BNT162b2) in the SCCS analysis. We did not observe any increased risk of neutropenia following CoronaVac vaccination in neither nested casecontrol (Table 3 ) nor SCCS analysis (Table 4 ). There was an increased risk after second dose of BNT162b2 in nested casecontrol analysis (aOR 2.74, 95% CI 1.63-4.61, Table 3 ). However, such association was not observed in the SCCS analysis (Table 4) .

On the other hand, there was no association after the first dose of BNT162b2 in the nested case-control analysis, but a lower risk was observed in the SCCS analysis (day14-27, IRR 0.28, 95% CI 0.10-0.85, Table 4 ). Similar results were obtained in the additional analysis excluding COVID-19 cases and using a longer time period of 84 days (Tables S8-S11 ). In subgroup analysis, an increased risk was observed only in people aged <60 in the nested case-control analysis (Tables S4-S7 ).

This real-world study showed an increased risk of leukopenia following the second dose of BNT162b2 as shown in both nested case-control and SCCS analyses. We observed an increased risk of Most findings were consistent in the nested case-control and SCCS analyses. However, we observed an increased risk of neutropenia following BNT162b2 vaccination in the nested case-control but not in the SCCS analysis. Indeed, nested case-control analysis could have residual confounding that might bias the estimates. Therefore, SCCS analysis was conducted to account for such residual confounding, and the results in the SCCS did not support the association between risk of neutropenia and BNT162b2. Further investigation is warranted to validate the findings.

The mechanism of leukopenia after BNT162b2 vaccination is unclear. However, decreased WBC counts after influenza vaccination was reported in early case reports, 34, 35 suggesting that the adverse events could be due to a general immune response rather than a vaccine-specific effect. In agreement with this hypothesis, the association was only observed in the first 2 weeks of the second dose but not in the first dose in our study. Indeed, a recent study in Hong Kong by Lim et al. 36 showed that the antibody concentrations after the sec- 

We observed an increased risk of leukopenia shortly after the second dose of BNT162b2, but the incidence was much lower than in people with SARS-CoV-2 infection. We did not observe any risk of hematological abnormalities following CoronaVac vaccination. The findings suggested that the beneficial effects of COVID-19 vaccines, Cor-onaVac and BNT162b2, still outweigh the risk of hematological abnormalities.

and Medical Research Council in Australia, and also received speaker fees from Janssen and Medice in the previous 3 years. He is also an independent nonexecutive director of Jacobson Medical in Hong Kong.

Chor-Wing Sing designed the study, performed data analysis, and wrote the manuscript. Casey Tze Lam Tang performed data analysis.

Min Fan assisted in the study design and data analysis. Celine Sze Ling 

Data will not be available for others as the data custodians have not given permission.

Chor-Wing Sing https://orcid.org/0000-0002-2180-3676

Anskar Yu-Hung Leung https://orcid.org/0000-0001-9975-8687

Ian Chi Kei Wong https://orcid.org/0000-0001-8242-0014

An interactive web-based dashboard to track COVID-19 in real time

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, doubleblind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study

Use of the selfcontrolled case-series method in vaccine safety studies: review and recommendations for best practice

Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study

Hospital Authority. Hospital Authority Statistical Report

Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation

Cardiovascular outcomes associated with use of clarithromycin: population based study

Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study

Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy

The Government of the Hong Kong Special Administrative Region. COVID-19 Vaccination Programme

Clinical characteristics of coronavirus disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study

Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes

Department of Health and Human Services NIH National Cancer Institute Common terminology criteria for adverse events (CTCAE) Version 4.0

Self-controlled case series studies: A modelling guide with R

MMR vaccine and idiopathic thrombocytopaenic purpura

Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Surveillance for adverse events after COVID-19 mRNA vaccination

Haematological changes associated with influenza vaccination in people aged over 65: case report and prospective study

Vaccination induced neutropenia

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Hematologic toxicity of sodium valproate

Delayed onset of clozapineinduced leucopenia

Benign ethnic neutropenia

Population By-census-Thematic Report: Ethnic Minorities